On 30 June 2021, Johnson & Johnson Innovation will host a virtual scientific event on state-of-the-art developments in neuroimmunology, bringing together entrepreneurs, start-ups, researchers, and scientists from across Europe and beyond.
The successes of therapeutics targeting inflammatory mechanisms in relapsing and remitting multiple sclerosis have led to neuroimmunology emerging as an important new paradigm in central nervous system (CNS) disorders.1 In neurodegenerative disorders like Alzheimer’s disease and Parkinson’s disease, human disease genetics strongly implicate several inflammatory pathways such as microglial signaling and complement.2 Moreover, recent research implicates inflammation in psychiatric disorders such as schizophrenia and major depressive disorder.3